Try Fund Library Premium
For Free with a 30 day trial!
Health Care Equity
Click for more information on Fundata’s FundGrade
Click for more information on Fundata’s FundGrade.
|
Close (12-12-2025) |
$37.43 |
|---|---|
| Change |
-$0.40
(-1.06%)
|
| Open | - |
|---|---|
| Day Range | - - - |
| Volume | 0 |
As at November 30, 2025
As at November 30, 2025
Loading...
Loading...
Inception Return (April 26, 2022): 0.03%
| Row Heading | Return | Annualized Return | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Mth | 3 Mth | 6 Mth | YTD | 1 Yr | 2 Yr | 3 Yr | 4 Yr | 5 Yr | 6 Yr | 7 Yr | 8 Yr | 9 Yr | 10 Yr | |
| Fund | 7.90% | 26.21% | 38.85% | 18.58% | 12.05% | 17.98% | 0.84% | - | - | - | - | - | - | - |
| Benchmark | 7.21% | 13.51% | 18.59% | 12.85% | 9.19% | 12.51% | 7.70% | 6.84% | 7.73% | 8.59% | 8.64% | 9.53% | 10.46% | 8.79% |
| Category Average | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Category Rank | 14 / 51 | 2 / 51 | 1 / 51 | 5 / 50 | 6 / 50 | 3 / 48 | 40 / 41 | - | - | - | - | - | - | - |
| Quartile Ranking | 2 | 1 | 1 | 1 | 1 | 1 | 4 | - | - | - | - | - | - | - |
| Return % | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund | -5.51% | 1.68% | -1.95% | -9.33% | -0.90% | -4.66% | 1.41% | 5.24% | 3.08% | 7.87% | 8.44% | 7.90% |
| Benchmark | -3.25% | 6.66% | 0.57% | -2.81% | -5.42% | -3.48% | 0.91% | -0.60% | 4.16% | 2.38% | 3.42% | 7.21% |
11.39% (November 2023)
-10.13% (December 2022)
| Return % | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Fund | - | - | - | - | - | - | - | - | -10.47% | 7.46% |
| Benchmark | 27.73% | -8.68% | 14.01% | 11.82% | 17.06% | 13.59% | 15.28% | -1.72% | 1.42% | 9.95% |
| Category Average | - | - | - | - | - | - | - | - | - | - |
| Quartile Ranking | - | - | - | - | - | - | - | - | 4 | 3 |
| Category Rank | - | - | - | - | - | - | - | - | 41/ 41 | 25/ 48 |
7.46% (2024)
-10.47% (2023)
| Name | Percent |
|---|---|
| US Equity | 64.51 |
| International Equity | 33.97 |
| Canadian Equity | 1.52 |
| Name | Percent |
|---|---|
| Healthcare | 95.71 |
| Other | 4.29 |
| Name | Percent |
|---|---|
| North America | 66.03 |
| Europe | 24.44 |
| Asia | 5.25 |
| Other | 4.28 |
| Name | Percent |
|---|---|
| Revolution Medicines Inc | 6.09 |
| Celcuity Inc | 5.66 |
| Regeneron Pharmaceuticals Inc | 5.08 |
| Incyte Corp | 4.88 |
| Genmab A/S | 4.61 |
| BEONE MEDICINES LTD | 4.28 |
| Merck & Co Inc | 4.27 |
| AstraZeneca PLC | 4.08 |
| Roche Holding AG - Partcptn | 3.78 |
| GSK plc | 3.72 |
iShares Genomics Immunology and Healthcare Index ETF
Median
Other - Health Care Equity
| Standard Deviation | 20.80% | - | - |
|---|---|---|---|
| Beta | 1.12% | - | - |
| Alpha | -0.06% | - | - |
| Rsquared | 0.33% | - | - |
| Sharpe | -0.05% | - | - |
| Sortino | 0.00% | - | - |
| Treynor | -0.01% | - | - |
| Tax Efficiency | - | - | - |
| Volatility |
|
- | - |
| Key Ratio | 1 Yr | 3 Yr | 5 Yr | 10 Yr |
|---|---|---|---|---|
| Standard Deviation | 19.99% | 20.80% | - | - |
| Beta | 0.98% | 1.12% | - | - |
| Alpha | 0.04% | -0.06% | - | - |
| Rsquared | 0.48% | 0.33% | - | - |
| Sharpe | 0.53% | -0.05% | - | - |
| Sortino | 0.82% | 0.00% | - | - |
| Treynor | 0.11% | -0.01% | - | - |
| Tax Efficiency | 97.87% | - | - | - |
| Start Date | April 26, 2022 |
|---|---|
| Instrument Type | Exchange Traded Fund |
| Share Class | Do-It-Yourself |
| Legal Status | Trust |
| Sales Status | Open |
| Currency | CAD |
| Distribution Frequency | Semi Annual |
| Assets ($mil) | $6 |
| 52 Week High | $39.90 |
| 52 Week Low | $26.09 |
| Annual Dividend | $0.17 |
| Annual Yield | - |
| Index | - |
| Shares Outstanding | - |
| Registered Plan Eligible | Yes |
| Exposure | - |
|---|---|
| Asset Class High | - |
| Asset Class Medium | - |
| Asset Class Low | - |
| Leveraged | - |
| Inverse | - |
| Advisor Series | - |
| Covered Call Strategy | No |
XDNA seeks to provide long-term capital growth by replicating, to the extent possible, the performance, net of expenses, of an Index selected at the discretion of BlackRock Canada that is composed of securities of issuers that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering, as determined by the Index Provider. XDNA currently seeks to replicate the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index.
XDNA’s current principal investment strategy is to employ a Replicating Strategy. In addition to or as an alternative to this strategy, XDNA may also invest by employing a Sampling Strategy, by investing in one or more iShares ETFs and/or through the use of derivatives.
| Portfolio Manager |
BlackRock Asset Management Canada Limited |
|---|---|
| Sub-Advisor |
BlackRock Institutional Trust Company, N.A.
|
| Fund Manager |
BlackRock Asset Management Canada Limited |
|---|---|
| Custodian |
- |
| Registrar |
- |
| Distributor |
- |
| MER | 0.44% |
|---|---|
| Management Fee | 0.39% |
Try Fund Library Premium
For Free with a 30 day trial!
Fund Library
